NCT01939587View on ClinicalTrials.gov

Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics

PHASE2CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

July 31, 2014

Conditions
Asthma
Interventions
DRUG

PBF-680 5 mg

DRUG

PBF-680 20 mg

DRUG

Placebo

Trial Locations (2)

08025

Hospital de la Santa Creu i Sant Pau, Barcelona

08302

Palobiofarma S.L. (molecule owner), Mataró

Sponsors

Collaborators (1)

Palo Biofarma, S.L
All Listed Sponsors
collaborator

Palo Biofarma, S.L

INDUSTRY

lead

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

OTHER

NCT01939587 - Study to Assess the Efficacy of a Single PBF-680 Oral Administration to Attenuate Adenosine 5'-Monophosphate Challenge-induced Airway Hyperresponsiveness in Mild-to-moderate Asthmatics | Biotech Hunter | Biotech Hunter